Приказ основних података о документу
Dyslipidemia in type 2 diabetes mellitus
Dislipidemija u dijabetes melitusu tip 2
dc.creator | Stefanović, Aleksandra | |
dc.creator | Zeljković, Aleksandra | |
dc.creator | Vekić, Jelena | |
dc.creator | Spasojević-Kalimanovska, Vesna | |
dc.creator | Jelić-Ivanović, Zorana | |
dc.creator | Spasić, Slavica | |
dc.date.accessioned | 2020-05-27T09:06:16Z | |
dc.date.available | 2020-05-27T09:06:16Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 0004-1963 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/3560 | |
dc.description.abstract | Type 2 diabetes mellitus is a chronic high-prevalence metabolic disease, which is characterized by hyperglycaemia, but also with lipid and protein metabolism disorders. Patients with type 2 diabetes have a high risk for cardiovascular disease (CVD) development and dyslipidemia is considered as a key marker of this increased risk. Hypertriglyceridemia, reduced high density lipoprotein cholesterol (HDL-c) concentrations, and a shift in low-density lipoprotein particles (LDL) distribution toward the small, triglycerides-rich particles, are the most important changes in the lipid profile in diabetes.Type 2 diabetes is a metabolic disorder associated with low grade inflammation and oxidative stress, so in this condition high density lipoprotein particles (HDL) also undergo structural and functional changes and, as a consequence, lose their atheroprotective role. Dyslipidemia treatment in type 2 diabetes patients younger than 40 and without any other risk factor for CVD development starts with changes in a lifestyle, but in patients older than 40 years, first line medications are statins.Glycemic and lipid control in type 2 diabetes patients significantly reduces CVD risk. | en |
dc.description.abstract | Dijabetes melitus tip 2 je hronično oboljenje sa visokom prevalencom, koje se karakteriše hiperglikemijom, ali i poremećajima u metabolizmu lipida i proteina. Pacijenti sa tipom 2 dijabetesa imaju visok rizik za razvoj kardiovaskularnih bolesti (KVB) i upravo se dislipidemija smatra ključnim uzročnikom ovog povećanog rizika. Hipertrigliceridemija, snižena koncentracija holesterola u lipoproteinskim česticama visoke gustine (HDL-h) i promena u raspodeli lipoproteinskih čestica niske gustine (LDL) u smeru većeg udela malih čestica, bogatih trigliceridima, predstavljaju najvažnije promene lipidnog profila koje se odnose na dislipidemiju u dijabetesu. Kako je dijabetes stanje kontinuirane blage inflamacije niskog stepena i stalne produkcije slobodnih radikala, HDL lipoproteinske čestice takođe podležu strukturnim i funkcionalnim promenama, usled čega gube svoje ateroprotektivne osobine. Terapija dislipidemije kod pacijenata mlađih od 40 godina bez prisutnih drugih faktora rizika za razvoj KVB počinje promenom životnog stila, a kod pacijenata starijih od 40 godina lekovi izbora u terapiji su statini. Glikemijska i lipidna kontrola kod pacijenata sa tipom 2 dijabetesa značajno umanjuje rizik od nastanka KVB. | sr |
dc.publisher | Beograd : Savez farmaceutskih udruženja Srbije | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175035/RS// | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-sa/4.0/ | |
dc.source | Arhiv za farmaciju | |
dc.subject | Cardiovascular disease risk | |
dc.subject | Diabetes mellitus type 2 | |
dc.subject | Dyslipidemia | |
dc.subject | dijabetes melitus tip 2 | |
dc.subject | dislipidemija | |
dc.subject | zik za razvoj kardiovaskularnih bolesti | |
dc.title | Dyslipidemia in type 2 diabetes mellitus | en |
dc.title | Dislipidemija u dijabetes melitusu tip 2 | sr |
dc.type | article | |
dc.rights.license | BY-SA | |
dcterms.abstract | Векић, Јелена; Зељковић, Aлександра; Спасић, Славица; Јелић-Ивановић, Зорана; Стефановић, Aлександра; Спасојевић-Калимановска, Весна; Дислипидемија у дијабетес мелитусу тип 2; | |
dc.citation.volume | 69 | |
dc.citation.issue | 5 | |
dc.citation.spage | 338 | |
dc.citation.epage | 348 | |
dc.citation.rank | M52 | |
dc.identifier.doi | 10.5937/arhfarm1905338S | |
dc.identifier.scopus | 2-s2.0-85080854356 | |
dc.identifier.fulltext | https://farfar.pharmacy.bg.ac.rs/bitstream/id/7639/Dyslipidemia_in_type_pub_2019.pdf | |
dc.type.version | publishedVersion |